Novartis and DSM trim jobs


Pharmaceutical firm Novartis and nutritional products specialist DSM are both set to cut jobs in Switzerland. Novartis’s will lose around 500 support and operational roles, while DSM aims to cut 120 staff. Novartis also plans to close a manufacturing plant in the US, affecting 525 employees.

Novartis says that the loss of patent exclusivity on blood pressure drug Diovan (valsartan) has reduced demand for products produced at the Suffern, New York, site. Following its phased closure over 2–3 years, the buildings will be demolished and equipment transferred elsewhere or sold, although company spokeswoman Julie Masow adds that the company is open to other proposals for the site.

Novartis adds that its planned product launches for 2014 will be accompanied by ‘several hundred’ new jobs in Switzerland, for example in supply chain management for its Sandoz generics arm and manufacturing for over-the-counter products.

DSM’s cuts are the fallout of reorganisation after recent acquisitions. The affected positions will come from both central support and R&D areas.


Related Content

Novartis to shut Horsham site

6 November 2013 Business

news image

UK research centre closure to result in the loss of 371 jobs as firm consolidates its global R&D base

Business roundup

31 March 2010 Business

news image

Industry news, April 2010

Most Read

Graphene sandwich turns water square

27 March 2015 Research

news image

Water trapped between graphene sheets transformed into new type of ice

Simple cooking changes make healthier rice

23 March 2015 Research

news image

Adding oil to water, cooling and reheating rice makes fibre-like resistant starch, reducing calories

Most Commented

Sewage offers attractive source of precious metals

27 March 2015 Research

news image

US Geological Survey team finds valuable metals in treated sewage and is working on the difficult problem of extraction

Thinking ahead

26 March 2015 Critical Point

news image

PhD courses must prepare students for a life after research, says Mark Peplow